A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma

Virology Journal

Volumn 8, Issue , 2011, Pages

  Takaoka, Hiroo ^a   Takahashi, Gen ^a   Ogawa, Fumi ^a   Imai, Tomoaki ^a   Iwai, Soichi ^a   Yura, Yoshiaki ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

cell fusion; herpes simplex virus mutant; oncolytic virotherapy; oral squamous cell carcinoma

Indexed keywords

BETA GALACTOSIDASE; ONCOLYTIC HERPES VIRUS; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; MOUTH CARCINOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROGENY; SQUAMOUS CELL CARCINOMA; VERO CELL; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CERCOPITHECUS; GENE DELETION; GENETIC RECOMBINATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HERPES SIMPLEX VIRUS 1; METHODOLOGY; NUDE MOUSE; PATHOLOGY; VIRUS CULTURE;

HUMAN HERPESVIRUS 1; MUS MUSCULUS; SIMPLEXVIRUS;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CERCOPITHECUS AETHIOPS; FEMALE; GENE DELETION; HERPESVIRUS 1, HUMAN; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PLAQUE ASSAY; RECOMBINATION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; VERO CELLS; VIRAL PROTEINS;

EID: 79958106941     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-294     Document Type: Article

References (32)

1. Cervical lymph node metastasis after local excision of early squamous cell carcinoma of the oral cavity. MJ Cunningham JT Johnson EN Myers VL Schramm Jr PB Thearle, Am J Surg 1986 152 361 366 10.1016/0002-9610(86)90305-3 3766864 (Pubitemid 16001463)
2. Cancer statistics, 2009. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun, CA Cancer J Clin 2009 59 225 249 10.3322/caac.20006 19474385
3. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by cytotoxic herpes simplex virus type 1 (G207). JF Carew DA Kooby MW Halterman HJ Federoff Y Fong, Hum Gene Ther 1999 10 1599 1606 10.1089/10430349950017608 10428205 (Pubitemid 29328204)
4. Oncolytic viruses move forward in clinical trials. K Rowan, J Natl Cancer Inst 2010 102 590 595 10.1093/jnci/djq165 20421567
5. Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles. HH Wong NR Lemoine Y Wang, Viruses 2010 2 78 106 10.3390/v2010078 20543907
6. Effective treatment of head and neck squamous cell carcinoma by oncolytic herpes simplex virus. RJ Wong SH Kim JK Joe JP Shah PA Johnson Y Fong, J Am Coll Surg 2001 193 12 21 10.1016/S1072-7515(01)00866-3 11442249 (Pubitemid 32591620)
7. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. BL Liu M Robinson ZQ Han RH Branston C English P Reay Y McGrath SK Thomas M Thornton P Bullock CA Love RS Coffin, Gene Ther 2003 10 292 303 10.1038/sj.gt.3301885 12595888 (Pubitemid 36305598)
8. Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice. A Israyelyan VN Chouljenko A Baghian AT David MT Kearney KG Kousoulas, Virol J 2008 5 68 10.1186/1743-422X-5-68 18518998
9. 134.5, gene nonessential for growth in culture. J Chou ER Kern RJ Whitley B Roizman, Science 1990 250 1262 1266 10.1126/science.2173860 2173860 (Pubitemid 120031840)
10. The gamma(1) 34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1 alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. B He M Gross B Roizman, Proc Natl Acad Sci USA 1997 94 843 848 10.1073/pnas.94.3.843 9023344
11. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant glioma. T Mineta SD Rabkin T Yazaki WD Hunter RL Martuza, Nature Med 1995 1 938 943 10.1038/nm0995-938 7585221
12. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. SJ Advani SM Chung SY Yan GY Gillespie JM Markert RJ Whitley B Roizman RR Weichselbaum, Cancer Res 1999 59 2055 2058 10232586 (Pubitemid 29217663)
13. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. N Kemeny K Brown A Covey T Kim A Bhargava L Brody B Guilfoyle NP Haag M Karrasch B Glasschroeder A Knoll G Getrajdman KJ Kowal WR Jarnagin Y Fong, Hum Gene Ther 2006 17 1214 1224 10.1089/hum.2006.17.1214 17107303 (Pubitemid 44975138)
14. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. M Nakamori X Fu F Meng A Jin L Tao RC Bast Jr X Zhang, Clin Cancer Res 2003 9 2727 2733 12855653 (Pubitemid 36842119)
15. The effect of temperature upon the production of herpes simplex virus in tissue culture. CE Wheeler, J Immunol 1958 81 98 106 13563885
16. Enhancement of herpes simplex virus-induced polykaryocyte formation by 12-o-tetradecanoyl phorbol 13-acetate: Association with the reorganization of actin filaments and cell motility. Y Yura J Kusaka T Bando S Yamamoto H Yoshida M Sato, Intervirology 2000 43 129 138 10.1159/000025038 11044806
17. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. H Takakuwa F Goshima N Nozawa T Yoshikawa H Kimata A Nakao A Nawa T Kurata T Sata Y Nishiyama, Arch Virol 2003 148 813 825 10.1007/s00705-002-0944-x 12664303 (Pubitemid 36425166)
18. Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer. A Nakao H Kimata T Imai T Kikumori O Teshigahara T Nagasaka F Goshima Y Nishiyma, Ann Oncol 2004 15 988 989 10.1093/annonc/mdh225 15151960 (Pubitemid 39004359)
19. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinomas. Y Fujimoto T Mizuno S Sugiura F Goshima S Kohno T Nakashima Y Nishiyama, Acta Otolaryngol 2006 126 1115 1117 10.1080/00016480600702100 16923721 (Pubitemid 44272841)
20. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. A Nakao H Kasuya TT Sahin N Nomura A Kanzaki M Misawa T Shirota S Yamada T Fujii H Sugimoto T Shikano S Nomoto S Takeda Y Kodera Y Nishiyama, Cancer Gene Ther 2011 18 167 175 10.1038/cgt.2010.65 21102422
21. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. S Andreansky L Soroceanu ER Flotte J Chou JM Markert GY Gillespie B Roizman RJ Whitley, Cancer Res 1997 57 1502 1509 9108452 (Pubitemid 27175567)
22. Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma. F Ogawa H Takaoka S Iwai K Aota Y Yura, Anticancer Res 2008 28 3637 3645 19189645
23. 134.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide. S Naito S Obayashi T Sumi S Iwai M Nakazawa K Ikuta Y Yura, Cancer Gene Ther 2006 13 780 791 10.1038/sj.cgt.7700957 16645620 (Pubitemid 44100491)
24. Selective extraction of polyoma DNA from infected mouse cell cultures. B Hirt, J Mol Biol 1967 26 365 369 10.1016/0022-2836(67)90307-5 4291934
25. Expression of annexin II in human atherosclerotic abdominal aortic aneurysms. T Hayashi E Morishita H Ohtake Y Oda K Ohta M Arahata Y Kadohira M Maekawa Y Ontachi M Yamazaki H Asakura A Takami S Nakao, Thromb Res 2008 123 274 280 10.1016/j.thromres.2008.03.027 18502476
26. Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus. Y Ushijima C Luo F Goshima Y Yamauchi H Kimura Y Nishiyama, Microbes Infect 2007 9 142 149 10.1016/j.micinf.2006.10.019 17218138 (Pubitemid 46227999)
27. A single amino acid substitution in the cytoplasmic tail of the glycoprotein B of herpes simplex virus 1 affects both syncytium formation and binding to intracellular heparan sulfate. A Diakidi-Kosta G Michailidou G Kontogounis A Sivropoulou M Arsenakis, Virus Res 2003 93 99 108 10.1016/S0168-1702(03)00070-4 12727347 (Pubitemid 36513891)
28. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. KD Smith JJ Mezhir K Bickenbach J Veerapong J Charron MC Posner B Roizman RR Weichselbaum, J Virol 2006 80 1110 1120 10.1128/JVI.80.3.1110-1120. 2006 16414988 (Pubitemid 43134068)
29. Oncolysis of pancreatic tumour cells by a gamma34.5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway. F Sarinella A Calistri P Sette G Pal C Parolin, Gene Ther 2006 13 1080 1087 10.1038/sj.gt.3302770 16554839
30. Utilizing ras signaling pathway to direct selective replication of herpes simplex virus-1. W Pan V Bodempudi T Esfandyari F Farassati, PLoS One 2009 4 6514 10.1371/journal.pone.0006514 19652721
31. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. AR Bateman KJ Harrington T Kottke A Ahmed AA Melcher MJ Gough E Linardakis D Riddle A Dietz CM Lohse S Strome T Peterson R Simari RG Vile, Cancer Res 2002 62 6566 6578 12438252 (Pubitemid 35364123)
32. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. D Watanabe F Goshima I Mori Y Tamada Y Matsumoto Y Nishiyama, J Dermatol Sci 2008 50 185 196 10.1016/j.jdermsci.2007.12.001 18226503